AIM: To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
PATIENTS AND METHODS: A Phase I clinical trial was performed with cohorts of three to six patients per group. Eligible patients had HRPC without distant metastases. The radiotherapy dose was escalated in a stepwise fashion as follows: 60, 65, and 70 Gy at levels 1, 2, and 3, respectively (25 fractions: levels 1-2, and 26 fractions: level 3).
RESULTS: Nine patients were enrolled. The radiotherapy dose was escalated from 60 to 70 Gy without any dose-limiting toxicity. The most common grade 1/2 toxicities were hematuria, dysuria, diarrhea and rectal-perirectal pain. The overall objective response rate was 9/9 (100%) (95% CI=66.4%-100%). The median time-to-progression was 19 months.
CONCLUSION: In the challenging setting of HRPC, HFRT up to 70 Gy with concurrent metronomic chemotherapy was well-tolerated and yielded encouraging disease control.
Written by:
Morganti AG, Massaccesi M, Caravatta L, Macchia G, Picardi V, Deodato F, Ippolito E, Mignogna S, Ferro M, Cilla S, Mattiucci GC, Valentini V. Are you the author?
Department of Radiotherapy, Research and Care Foundation "Giovanni Paolo II", Catholic University of Sacred Heart, Largo A. Gemelli 1, 86100 Campobasso, Italy.
Reference: Anticancer Res. 2013 Oct;33(10):4585-9.
PubMed Abstract
PMID: 24123034
UroToday.com Prostate Cancer Section
